Preclinical In Silico Evidence Indicates the Pharmacological Targets and Mechanisms of Mogroside V in Patients With Ovarian Cancer and Coronavirus Disease 2019

Yongming Li, Yudong Chen, Mulan Wei, Chaohe WeiFrontiers in Endocrinology 2022 · DOI

TL;DR

This study investigates the potential of Mogroside V, a natural compound from Siraitia grosvenorii, as a therapeutic agent for patients co-infected with ovarian cancer and COVID-19. Using in silico methods, researchers identified key molecular targets and pathways through which Mogroside V might exert its effects, suggesting it could be a promising candidate for further investigation.

What Problem Does This Paper Address?

The COVID-19 pandemic has presented unique challenges, particularly for vulnerable populations such as cancer patients. Individuals with cancer, especially those with ovarian cancer, appear to be at higher risk of severe COVID-19 outcomes, potentially due to compromised immune systems and tumor-induced immunologic injury. This creates an urgent need to identify therapeutic strategies that can address both conditions simultaneously or mitigate the increased risk associated with COVID-19 in cancer patients. While Mogroside V has shown promise for lung protection and anti-cancer effects, its specific role in co-infected ovarian cancer and COVID-19 patients remains unexplored. This paper aims to fill that gap by using computational approaches to predict its therapeutic potential.

Methods

The researchers employed a two-pronged computational approach:

  • Network Pharmacology: This method was used to identify potential drug targets and understand the complex biological networks involved.
  • Target Acquisition: They gathered known targets for Mogroside V, COVID-19, and ovarian cancer from various databases (Swiss Target Prediction, PharmMapper, Batman, UniProt, GeneCards, DrugBank, OMIM).
  • Intersection Analysis: They identified common targets between COVID-19 and ovarian cancer, and then further identified targets of Mogroside V that intersected with these common targets.
  • Protein-Protein Interaction (PPI) Network Construction: Using the STRING database and Cytoscape software, they built a PPI network to visualize the relationships between these targets.
  • Core Target Identification: Topological parameters within the PPI network were analyzed to identify "core" targets, which are considered more critical for therapeutic intervention.
  • Enrichment Analysis (GO and KEGG): The DAVID database was used to determine the biological processes (Gene Ontology - GO) and signaling pathways (Kyoto Encyclopedia of Genes and Genomes - KEGG) associated with these core targets. This helps understand how Mogroside V might be working.
  • Molecular Docking: This technique was used to predict the binding affinity and interaction between Mogroside V and its identified core targets at a molecular level.
  • Protein and Ligand Preparation: Structures of core target proteins (specifically VEGFA) and Mogroside V were obtained from public databases (PDB, PubChem) and prepared for docking.
  • Docking Simulation: AutoDock Vina software was used to simulate the binding of Mogroside V to the active site of the VEGFA protein.
  • Binding Energy Assessment: The free binding energy was calculated to quantify the strength of the interaction.

Datasets

The study utilized publicly available databases for its data:

  • Drug/Compound Databases: Swiss Target Prediction, PharmMapper, Batman, PubChem.
  • Protein/Gene Databases: UniProt, GeneCards, DrugBank, OMIM.
  • Disease-Specific Databases: Databases for COVID-19 and ovarian cancer targets.
  • Protein-Protein Interaction Database: STRING.
  • Bioinformatics Tools: Cytoscape, DAVID database.
  • Protein Structure Database: Protein Data Bank (PDB).

No new datasets or benchmarks were introduced in this study.

Key Insights and Ideas

  • Mogroside V as a Multifaceted Therapeutic: The study highlights Mogroside V's potential to simultaneously address aspects of both ovarian cancer and COVID-19, a critical need given the increased vulnerability of cancer patients to viral infections.
  • Identification of Key Molecular Players: The identification of 10 core targets (JUN, IL2, HSP90AA1, AR, PRKCB, VEGFA, TLR9, TLR7, STAT3, and PRKCA) provides a focused set of molecules for further investigation. These targets are involved in a range of cellular processes relevant to both cancer and viral infection.
  • VEGFA as a Promising Target: The molecular docking results showing a strong binding affinity between Mogroside V and VEGFA are particularly noteworthy. VEGFA is a known factor in angiogenesis (blood vessel formation) and is implicated in both cancer progression and potentially in the vascular complications seen in severe COVID-19.
  • Understanding Mechanistic Pathways: The GO and KEGG enrichment analyses provide crucial insights into the biological pathways Mogroside V might influence, such as cytokine signaling, immune responses (Th17 cell differentiation), and cellular processes related to viral entry and replication.

Key Results

  • 24 Candidate Targets Identified: The initial analysis revealed 24 potential targets for Mogroside V in the context of COVID-19 and ovarian cancer.
  • 10 Core Targets Identified: Through network analysis, 10 core targets were pinpointed, including JUN, IL2, HSP90AA1, AR, PRKCB, VEGFA, TLR9, TLR7, STAT3, and PRKCA.
  • Favorable Molecular Docking with VEGFA: Mogroside V demonstrated a strong binding affinity to VEGFA, with a free binding energy of -8.2 kcal/mol. This interaction involved hydrogen bonds with several key amino acid residues within the VEGFA protein.
  • Enrichment Analysis Revealed Key Pathways: The study identified relevant biological processes and signaling pathways, including cytokine receptor binding, cytokine activity, the HIF-1 signaling pathway, and Th17 cell differentiation.

Limitations and Future Work

  • In Silico Nature: The authors acknowledge that all findings are based on in silico (computational) analyses. This means experimental validation is crucial.
  • Need for Experimental Validation: The study explicitly states that further in vitro and in vivo experiments are necessary to confirm the predicted drug targets, pharmacological mechanisms, and the therapeutic efficacy of Mogroside V.
  • Docking Capabilities: While molecular docking showed promising results, the in silico docking capabilities need to be validated experimentally.

The future work clearly lies in translating these computational predictions into laboratory experiments to confirm the therapeutic potential of Mogroside V for patients with ovarian cancer and COVID-19.

Summary updated

Abstract

The borderless transmission of coronavirus remains uncontrolled globally. The uncharted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant reduces the therapeutic efficacy of vaccines against coronavirus disease 2019 (COVID-19). Clinical observations suggest that tumour cases are highly infected with coronavirus, possibly due to immunologic injury, causing a higher COVID-19-related death toll. Presently, screening of candidate medication against coronavirus is in progress. Mogroside V, a bioactive ingredient of <i>Siraitia grosvenorii</i>, has been reported in China to have lung-protective and anticancer effects. The current study used network pharmacology and molecular docking to unlock the potential drug targets and remedial mechanisms of mogroside V against patients with ovarian cancer with COVID-19. We identified 24 related targets of mogroside V in patients with ovarian cancer and COVID-19 and characterised another 10 core targets of mogroside V against COVID-19 ovarian cancer, including Jun, IL2, HSP90AA1, AR, PRKCB, VEGFA, TLR9, TLR7, STAT3, and PRKCA. The core targets' biological processes and signalling pathways were revealed by enrichment analysis. Molecular docking suggested favourable docking between core target protein and mogroside V, including vascular endothelial growth factor A (VEGFA). These findings indicated that mogroside V might be a potential therapeutic agent in the mitigation of COVID-19 ovarian cancer.
BibTeX
@inproceedings{li2022preclinical,
  author = {Yongming Li and Yudong Chen and Mulan Wei and Chaohe Wei},
  title = {{Preclinical In Silico Evidence Indicates the Pharmacological Targets and Mechanisms of Mogroside V in Patients With Ovarian Cancer and Coronavirus Disease 2019}},
  booktitle = {Frontiers in Endocrinology},
  year = {2022},
  doi = {10.3389/fendo.2022.845404},
}
Figure